Profound Medical Corp
Company Profile
Business description
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Contact
2400 Skymark Avenue
Unit 6
MississaugaONL4W 5K5
CANT: +1 647 476-1350
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
stocks
Alphabet returns on AI investments accelerating
stocks
We lift our fair value estimate for this ASX energy play
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,888.90 | 18.40 | 0.21% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 25,787.06 | 324.78 | -1.24% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,204.20 | 713.26 | -1.19% |
| NZX 50 Index | 12,845.05 | 74.75 | 0.59% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,664.10 | 23.90 | 0.28% |
| SSE Composite Index | 4,111.02 | 3.50 | 0.09% |